Zacks Research Comments on Esperion Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPRFree Report) – Equities research analysts at Zacks Research issued their FY2026 earnings estimates for shares of Esperion Therapeutics in a report issued on Tuesday, March 19th. Zacks Research analyst K. Das expects that the biopharmaceutical company will post earnings per share of $4.13 for the year. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.66) per share.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same period in the previous year, the business posted ($0.76) earnings per share.

A number of other equities research analysts have also recently issued reports on ESPR. Bank of America cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 3rd. HC Wainwright dropped their target price on shares of Esperion Therapeutics from $22.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research report on Tuesday, February 27th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.33.

View Our Latest Research Report on Esperion Therapeutics

Esperion Therapeutics Trading Up 1.5 %

Shares of Esperion Therapeutics stock opened at $2.08 on Wednesday. The company has a 50-day simple moving average of $2.42 and a 200 day simple moving average of $1.76. Esperion Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.34.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its position in Esperion Therapeutics by 30.0% in the 2nd quarter. FMR LLC now owns 8,669 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 2,003 shares in the last quarter. Private Portfolio Partners LLC acquired a new stake in Esperion Therapeutics in the 4th quarter valued at about $30,000. Principal Financial Group Inc. acquired a new stake in Esperion Therapeutics in the 1st quarter valued at about $49,000. Amalgamated Bank increased its position in Esperion Therapeutics by 18.6% in the 4th quarter. Amalgamated Bank now owns 12,490 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 1,960 shares in the last quarter. Finally, Invesco Ltd. acquired a new stake in Esperion Therapeutics in the 1st quarter valued at about $65,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Esperion Therapeutics Company Profile

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Read More

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.